Home › Liposarcoma › Connecticut › New Haven
Liposarcoma clinical trials in New Haven, CT
3 studies for Liposarcoma are looking for participants at sites in and around New Haven (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
RecruitingPhase 3
- Yale University, New Haven
- Smilow Cancer Hospital-Derby Care Center, Derby · 8 mi away
- Smilow Cancer Hospital Care Center - Guilford, Guilford · 13 mi away
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
RecruitingPhase 2
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Yale-New Haven Hospital-Yale Cancer Center, New Haven
- Smilow Cancer Hospital Phase 1 Unit, New Haven
- and 1 more
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
RecruitingPhase 3
- Yale University, New Haven
- Yale-New Haven Hospital North Haven Medical Center, North Haven · 7 mi away
- Smilow Cancer Hospital-Derby Care Center, Derby · 8 mi away
- and 1 more
Liposarcoma trials in other cities
- Houston, TX11 studies
- New York City, NY7 studies
- Boston, MA7 studies
- St. Louis, MO5 studies
- Queens, NY5 studies
- Chicago, IL5 studies
- Nashville, TN4 studies
- Miami, FL4 studies
- Tampa, FL4 studies
- Atlanta, GA4 studies
- Edison, NJ4 studies
- Seattle, WA4 studies
Other studies in New Haven
- Non-Small Cell Lung Cancer40 studies
- Breast Cancer38 studies
- Cancer (all types)35 studies
- Lung Cancer24 studies
- Colorectal Cancer23 studies
- Head and Neck Squamous Cell Carcinoma22 studies
- Metastatic Cancer22 studies
- Prostate Cancer22 studies
- Ovarian Cancer20 studies
- Opioid Overdose19 studies
- Acute Myeloid Leukemia18 studies
- Alcohol Use Disorder (AUD)18 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.